Britain's NHS will cover Mounjaro for weight management starting in March

Britain's drug-cost watchdog gave final approval on Dec. 23 for Mounjaro (tirzepatide) to be offered through the National Health Service for weight management, with the first NHS patients able to start treatment in March ^[1]. The National Institute for Health and Care Excellence, known as NICE, had said on Dec. 5 that it intended to recommend the drug and would publish final guidance on Dec. 23 if no appeals were lodged ^[2].

NICE recommends Mounjaro, alongside diet and exercise changes, for people with at least one weight-related condition, such as heart disease or type 2 diabetes, and a body mass index above 35 ^[1][2]. Those are the same eligibility rules NICE issued in March 2023 for Wegovy, Novo Nordisk's obesity medication ^[1][2]. NICE's guidance covers England ^[2].

About 3.4 million people meet those criteria, but the rollout is phased. Roughly 220,000 people are expected to receive the medicine during the first three years, with those who have the highest clinical need prioritized, and NICE will review the situation within that period ^[2]. NICE said the size of the eligible group means the rollout "has to be carefully managed to ensure healthcare professionals can continue to meet the full range of health needs of all their patients" ^[2].

The timing is split by where a patient is already being treated. The first NHS patients can start receiving Mounjaro 90 days after the guidance was published if they are already treated at a specialist NHS weight management service, or 180 days after publication if they are not, NICE said ^[2]. Reuters reported that the drug will be available through the state health system for some patients from March ^[1].

The NHS will pay 122 pounds ($153) per patient per month for the highest dose, a price NICE judged to be cost-effective given the costs to the health system of obesity and related conditions ^[1]. In clinical trials, the drug led to an average weight loss of nearly 23% ^[1][2]. Mounjaro is part of a class of medicines known as GLP-1 analogs, originally developed to control blood sugar in people with type 2 diabetes and also found to suppress appetite and promote a feeling of fullness ^[1][2].

Mounjaro launched in Britain in February 2024 but until now had been available only to people paying privately, mainly through online pharmacies ^[1][2]. Lilly said it welcomed NICE's recommendation and understood that it would require a phased rollout ^[2]. Nearly one in three adults in Britain are obese, the highest rate in Europe, according to a 2019 Organisation for Economic Cooperation and Development report, above the European Union average of 16.5%, according to EU statistics ^[2].

Why it matters for patients

This decision applies to Britain's publicly funded health system. It does not change whether tirzepatide is available in the United States, what it costs there, or whether US insurance plans cover it, and no such changes have been reported.

The eligibility bar is high: a BMI above 35 plus at least one weight-related condition. The rules mirror those Britain set for Wegovy in 2023, so two competing drugs for weight management now sit under the same public coverage criteria in that country ^[1][2].

The 122 pounds ($153) per month is a price negotiated for one public payer at the highest dose, not a US retail or insurance price, and the two are not comparable on the basis of this figure alone ^[1].

Availability is also limited even for people who qualify. About 220,000 of roughly 3.4 million eligible people in England are expected to be treated in the first three years, and those with the highest clinical need go first ^[2].

What happens next

• Dec. 23, 2024: NICE published final guidance recommending Mounjaro, after saying it would do so if no appeals were filed ^[1][2].
• March 2025: the drug becomes available through the NHS for some patients, Reuters reported ^[1].
• 90 days after publication: patients already treated at a specialist NHS weight management service can start receiving Mounjaro ^[2].
• 180 days after publication: patients not already in a specialist service can start receiving it ^[2].
• Within the first three years: NICE will review the rollout, with about 220,000 people expected to be treated in that period ^[2].